To Evaluate Efficacy and Safety in TG-2349 Combination With DAG181 (± Ribavirin) in HCV Genotype I Infected Patients

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2018
The purpose of this phase II study is to evaluate the efficacy and safety in TG‐2349 combination with DAG181 (± Ribavirin) in treatment naïve subjects with chronic hepatic C virus genotype I infection. Approximately 132 subjects will be enrolled in this study and divided into six groups: Group 1 to 4: Chronic hepatics C virus (HCV) genotype 1 infected, treatment naïve, non‐cirrhotic subjects. Group 5 to 6: Chronic hepatics C virus (HCV) genotype 1 infected, treatment naïve, cirrhotic subjects.
Epistemonikos ID: b3962da097e8f8a89a83049ce2a3d9a81bf5f41b
First added on: Mar 23, 2020